Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and activ...
Key Highlights: Implications: The launch positions Eisai to capture first-mover advantage in India’s underpenetrated dementia market, where prevalence is already large and expected t...
Key Highlights: Implications: The approval broadens AstraZeneca’s trastuzumab deruxtecan franchise in India from later-line metastatic use into the earlier, potentially larger HER2-positiv...
Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Key Highlights: Implications: This approval moves Enhertu + Perjeta into the front line of HER2‑positive metastatic breast cancer care in India, displacing taxane + tra...
Key Highlights: Implications: MSN joins the generics stampede, slashing premium GLP-1 prices and handing endocrinologists budget-friendly options for mass diabetes management.&n...
Key Highlights: Implications: Invisalign obliterates metal expander pain points, handing orthodontists a sleek digital alternative that skyrockets teen compliance and parental b...
